| Literature DB >> 31832549 |
Muhammad B Hammami1, Kavya M Reddy1, Pratik Pandit2, Elie J Chahla1, Nabeel Koro1, Matthew J Schuelke3, Christine Hachem1.
Abstract
BACKGROUND AND AIM: Same-day double upper and lower gastrointestinal endoscopy is frequently performed due to overlapping indications. However, it is unclear whether an upper-lower (U-L) or lower-upper (L-U) sequence is optimal. We analyzed the effect of sequence on total procedure time and sedation use.Entities:
Keywords: colonoscopy; digestive system endoscopy; endoscopy
Year: 2019 PMID: 31832549 PMCID: PMC6891031 DOI: 10.1002/jgh3.12203
Source DB: PubMed Journal: JGH Open ISSN: 2397-9070
Demographics of study participants
| Total ( | U‐L ( | L‐U ( | |
|---|---|---|---|
| Age, mean (SD), year | 55.7 (11) | 54 (11.8) | 57.7 (9.7) |
| BMI, mean (SD), kg/m2 | 29.96 (7.9) | 30.6 (7.7) | 29.4 (8.1) |
| Female | 56 (56%) | 24 (48%) | 32 (64%) |
| Diabetes mellitus | 26 (26%) | 13 (26%) | 13 (26%) |
| Inflammatory bowel disease | 2 (2%) | 2 (4%) | 0 (0%) |
| Hypertension | 46 (46%) | 24 (48%) | 22 (44%) |
| Chronic kidney disease | 11 (11%) | 7 (14%) | 4 (8%) |
| Obstructive sleep apnea | 19 (19%) | 9 (18%) | 10 (20%) |
| Cirrhosis | 21 (21%) | 14 (28%) | 7 (14%) |
| Heart disease | 18 (18%) | 9 (18%) | 9 (18%) |
| Lung disease | 30 (30%) | 9 (18%) | 21 (42%) |
| History of abdominal surgeries | 60 (60%) | 28 (56%) | 32 (64%) |
| Tobacco use | 52 (52%) | 27 (54%) | 25 (50%) |
| History of malignancy | 12 (12%) | 5 (10%) | 7 (14%) |
U‐L indicates patients randomized to the upper followed by lower GI endoscopy sequence.
L‐U indicated patients randomized to the lower followed by upper GI endoscopy sequence.
BMI, body mass index; GI, gastrointestinal.
Indications for endoscopic procedure
| Total ( | U‐L ( | L‐U ( | |
|---|---|---|---|
| Upper endoscopy indication | |||
| GI Bleeding | 39 (39%) | 20 (40%) | 19 (38%) |
| Malignancy | 8 (8%) | 5 (10%) | 3 (6%) |
| Other symptoms | 52 (52%) | 25 (50%) | 27 (54%) |
| Lower endoscopy indication | |||
| GI Bleeding | 21 (21%) | 9 (18%) | 12 (24%) |
| Malignancy | 53 (53%) | 30 (60%) | 23 (46%) |
| Other symptoms | 26 (26%) | 11 (22%) | 15 (30%) |
U‐L indicates patients randomized to the upper followed by lower GI endoscopy sequence.
L‐U indicated patients randomized to the lower followed by upper GI endoscopy sequence.
Indication GI Bleeding represents endoscopy performed for gastroesophageal variceal screening/surveillance, anemia, hematochezia, melena, or hematemesis.
Indication Malignancy represents endoscopy performed for weight loss or Barrett's esophagus screening/surveillance.
Indication GI symptoms represents endoscopy performed for evaluation of celiac disease, pain, heartburn, dyspepsia, dysphagia, early satiety, or diarrhea.
GI, gastrointestinal.
Procedure‐related factors
| Total ( | U‐L ( | L‐U ( | |
|---|---|---|---|
| Time of first procedure | |||
| After noon | 63 (63%) | 34 (68%) | 29 (58%) |
| Before noon | 37 (37%) | 16 (32%) | 21 (42%) |
| Type of sedation | |||
| Conscious sedation | 14 (14%) | 9 (18%) | 5 (10%) |
| Monitored anesthesia care | 86 (86%) | 41 (82%) | 45 (90%) |
| Presence of trainee | 50 (50%) | 26 (52%) | 24 (48%) |
| Performance of gastric biopsies | 72 (72%) | 33 (66%) | 39 (78%) |
| Polypectomy from ascending colon | 17 (17%) | 9 (18%) | 8 (16%) |
| Polypectomy from transverse colon | 23 (23%) | 8 (16%) | 15 (30%) |
| Polypectomy from descending colon | 16 (16%) | 6 (12%) | 10 (20%) |
| Polypectomy from recto‐sigmoid colon | 25 (25%) | 11 (22%) | 14 (28%) |
| Polypectomy from cecum | 9 (9%) | 6 (12%) | 3 (6%) |
| Presence of adenomas on pathology | 36 (36%) | 15 (30%) | 21 (42%) |
U‐L indicates patients randomized to the upper followed by lower GI endoscopy sequence.
L‐U indicated patients randomized to the lower followed by upper GI endoscopy sequence.
GI, gastrointestinal.
Mean procedure times in upper–lower versus lower–upper groups
| Mean endoscopic procedure times | Upper–lower ( | Lower–upper ( |
|
|---|---|---|---|
| EGD time (SD), min | 9.8 (6.0) | 10 (4.4) | 0.82 |
| Colonoscopy time (SD), min | 26.8 (13.4) | 25.6 (12.9) | 0.64 |
| Time between (SD), min | 5.3 (1.1) | 7.4 (2.9) | <0.001 |
| Total time (SD), min | 41.9 (16.2) | 43.0 (14.5) | 0.73 |
P value is two‐sided.
U‐L indicates patients randomized to the upper followed by lower GI endoscopy sequence.
L‐U indicated patients randomized to the lower followed by upper GI endoscopy sequence.
EGD, esophagogastroduodenoscopy; GI, gastrointestinal.
Mean sedative doses in upper–lower versus lower–upper groups
| Mean endoscopic sedative doses | Upper–lower ( | Lower–upper ( |
|
|---|---|---|---|
| Total diphenhydramine (SD), mg | 5.5 (15.4) | 4.5 (14.0) | 0.74 |
| Time fentanyl (SD), μg | 71.5 (119.3) | 77.6 (164.02) | 0.83 |
| Time midazolam (SD), mg | 1.6 (2.5) | 1.4 (2.7) | 0.69 |
| Total propofol (SD), mg | 437.4 (351.4) | 444.5 (256.0) | 0.91 |
P value is two‐sided.
U‐L indicates patients randomized to the upper followed by lower GI endoscopy sequence.
L‐U indicated patients randomized to the lower followed by upper GI endoscopy sequence.
GI, gastrointestinal.
Subgroup analysis of monitored anesthesia care patients: (n = 86)
| Upper–lower ( | Lower–upper ( |
| |
|---|---|---|---|
| Mean endoscopic procedure times | |||
| Total EGD time (SD), min | 8.9 (4.3) | 9.6 (4.0) | 0.47 |
| Total colonoscopy time (SD), min | 26.3 (12.2) | 25.8 (13.0) | 0.84 |
| Time between procedures(SD), min | 5.0 (1.8) | 7.2 (2.5) | <0.001 |
| Total procedure time (SD), min | 40.1 (14.1) | 42.5 (14.6) | 0.46 |
| Mean endoscopic sedative doses | |||
| Total diphenhydramine (SD), mg | 0.0 (0) | 1.1 (7.5) | 0.32 |
| Time fentanyl (SD), μg | 533.4 (314.3) | 493.9 (219.2) | 0.50 |
| Time midazolam (SD), mg | 0.6 (0.9) | 0.7 (1.5) | 0.73 |
| Total propofol (SD), mg | 533.4 (314.3) | 493.9 (219.2) | 0.50 |
P value is two‐sided.
U‐L indicates patients randomized to the upper followed by lower GI endoscopy sequence.
L‐U indicated patients randomized to the lower followed by upper GI endoscopy sequence.
EGD, esophagogastroduodenoscopy; GI, gastrointestinal.